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Many patients present to a pri-
mary care setting with symptoms
of a mood disorder. These symp-
toms may be indicative of an
anxiety disorder or a depressive
disorder, but they may also repre-
sent bipolar disorder, which is
more common than many practi-
tioners think. Correctly diagnos-
ing bipolar disorder can be
complex, because patients tend to
seek treatment when they are
experiencing the symptoms of
depression or anxiety rather than
mania or hypomania. Comorbid
disorders such as substance abuse
and anxiety disorders may com-
plicate the clinical presentation.
Failing to correctly diagnose
bipolar disorder can have serious
consequences in terms of patients'
morbidity and mortality, quality
of life, and financial costs.
Primary care nurse practitioners
(NPs) frequently see patients who
have both medical and psychiatric
diagnoses.'' The psychiatric diag-
nosis may present in a variety of
guises and may be hidden under
an array of sonnatic complaints.'
Mentally healthy individuals expe-
rience a vast range of moods
throughout their lifetime; this nor-
mal fluctuation may fall between
euphoria and depression. How-
ever, extreme mood swings may
alter a person's thoughts, feelings.
physical health, behavior, and
social functioning, and may repre-
sent a more serious cause such as
unipolar depression (ie, major
depression) or bipolar disorder
(alternation between elevated and
depressed mood states).^'
Because of the limited time
frame available to evaluate each
patient, NPs may have difficulty
distinguishing betv îeen a normal
fluctuation of mood and a more
extreme fluctuation of mood
indicative of a more serious psychi-
atric disorder.' As providers of
holistic care, as well as being the
sole healthcare providers that many
patients see, NPs are responsible
for recognizing, diagnosing, and
treating mental illnesses, as well as
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making appropriate referrals.' The
diagnosis of bipolar disorder is
often under-recognized because
patients tend to report depression,
anxiety, insomnia, or substance
abuse, while ignoring their epi-
sodes of mania or hypomania.''̂
• Unipolar depression: loss of
interest or pleasure in all or
almost all activities most of the
day, nearly every day; changes
in appetite and v̂ êight;
decreased energy, concentra-
tion and memory; increased
feelings of hopelessness, help-
lessness, guilt, fatigue, irritabil-
ity or restiessness;
• Anxiety: excessive worry that





• Mania: abnormally elevated,
expansive, or irritable mood
characterized by grandiosity,
decreased need for sleep, pres-
sured speech, flight of ideas,
distraaibility, psychomotor
agitation, and excessive in-
volvement in pleasurable
activities without regard to the
consequences; and
• Hypomania: an abnormality
of mood resembling mania
but of lesser intensity.'
If patients are experiencing
acute mania or hypomania, which
might signal a diagnosis of bipolar
disorder, they are more likely to
present to an emergency depart-




Reviewing the history of mood dis-
orders provides insight into the
persisting stigmata associated with
mental illness. Mood disorders
were initially described by the
ancient Greeks and Romans, who
coined tbe terms mania and melan-
cholia and identified them as two
distinct disorders."' One treatment
recommended for euphoric, agitat-
ed, or melancholic patients was
bathing in the waters of northern
Italian spas. A natural supply of
lithium salts was later discovered to
be present in these waters.**
In 300 BC, Hippocrates des-
cribed the link between "the four
humors"—which he labeled blood,
black bile, yellow bile, and
phlegm—and physical health.'"
Hippocrates' support of the physi-
cal origin of mental disorders was
contrary to the popular belief of
the time period—that mental ill-
ness was caused by magical or
supernatural forces.*
In the second century AD,
Areteus of Cappadocia thought
that euphoria and depression
might coexist as two attributes of
one disorder."'"" After the decline
of the Roman Empire, devil pos-
session was believed to be the
cause of mania and depression.
Treatments included restraints,
euthanasia, exotic potions, blood-
letting, and application of electric
eels to the skull."
The term manico-melancolicus
was coined by Théophile Bonet in
1686 to describe the relationship
between mania and melancholia."
A more modem conceptualization
was described by lean-Pierre Fairet
in the 1850s as folie circulaire,
meaning "circular insanity"; folie
can also mean "double form,"
which describes the attacks of both
mania and depression that charac-
terize bipolar disorder."'̂  This early
identification encompassed a wide
range of affective disorders that
included unipolar and bipolar
depression." In 1921, Emil Kraepelin
published Manic-Depressive Insanity
and Paranoia, which suggested for the
first time that severe psychotic depres-
sion could have altemating forms of
mania and severe melancholy." Since
then, the complicated subtypes of
bipolar disorder have been identified
and diagnostic criteria established.
Incidence
Each year, 20% to 23% of US
adults suffer from depression and
38% from an anxiety disorder."'*
The incidence of bipolar I disorder
is approximately 1%,'"'"' but if the
broader spectrum of bipolar disor-
ders is included, then the incidence
may be as high as 8%,"^ '̂ leading
the World Health Organization
(WHO) to identify bipolar disor-
der as the sixth leading cause of
disability for persons aged 15 to
65.'"" Two thirds of patients with
bipolar disorder have impairment
in both occupational and function-
al domains, and instability in
social and intimate relationships.
Bipolar disorder is equally com-
mon in men and women,^'"'
although research indicates that
women are 3 times more likely
than men to experience rapid
cycling."-̂ " Further studies have
indicated that bipolar II disorder
may be more common in women
than in men.'"^* The incidence of
bipolar disorder in children and
adolescents is more difficult to
determine. In the past, this disorder
was thought to be rare or nonexis-
tent in children." Findings in one
National Institute of Mental Health
(NIMH) study suggested that bipo-
lar disorder was as common in
young people as it is in adults." A
study on 82 children with pédiatrie
bipolar disorder (mean age, 11
years), showed that in 74% of the
participants, psychopathologic
manifestations such as mood and
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sleep disturbances, hyperactivity,
aggression, and anxiety v̂ êre recog-
nized before age 3 years." Ninety
percent of the participants had a
family history of mood or sub-
stance abuse disorders."
Etiology and Pathophysiology
The etiology of bipolar disorder is
complex, and seems to be related
to the interaction of various genet-
ic and non-genetic factors.̂ '̂̂ " The
genetic link has been suggested by
the results of family, twin, and
adoption studies. "'̂ ^̂ '' First-degree
relatives of a person with bipolar
disorder, as compared with the
general population, are approxi-
mately 7 times more likely to
develop the disorder. ̂^
Despite the identification of a
genetic link, the understanding of
the pathophysiology of bipolar
disorder is limited.̂ " Several differ-
ent neurotransmitters have been
linked to bipolar disorder; these
links have been based on patients'
responses to psychoactive agents.
For example, patients treated with
reserpine incidentally experience
depression. Because reserpine de-
pletes catecholamines from nerve
tissues, researchers hypothesized
that an increase in epinephrine
and norepinephrine induces
mania, whereas a decrease in these
neurotransmitters causes depres-
sion. Cocaine, another drug that
acts on this neurotransmitter sys-
tem, exacerbates mania. Levodopa
also exacerbates mania, suggesting
that dopamine and serotonin are
linked to bipolar disorder. Finally,
hormonal imbalances and disrup-
tions of the hypothalamic-pitu-
TABLE 1 BIPOLAR SPECTRUM DISORDERS'
BIPOLAR I DISORDER: Presence or history of at least one manic episode,
with or without o history of major depressive episode(s) that cannot be
accounted for by another disorder; the episode must have lasted at least a
week (unless functional impairment is so great that hospitalization is
required)
BIPOLAR II DISORDER: Presence or history of at least one hypomanic
episode and one or more major depressive episode(s) that cannot be
accounted for by another disorder
• CYCLOTHYMIA: Presence of numerous periods of hypomanic symptoms
interspersed with numerous periods of depressive symptoms, but to a
lesser degree than those occurring with bipolar I or bipolar II, and
occurring almost consistently during a 2-year time period (1 year of
symptoms in children and adolescents)
• BIPOLAR DISORDER, NOT OTHERWISE SPECIFIED: Residual diagnostic
category for bipolar features that do not meet diagnostic criteria for bipolar
I, bipolar II, or cyclothymia. This diagnostic category may be used during
the period of initial diagnosis if a secondary cause for the symptoms such
as substance abuse or a medical condition is being considered.
Adapted from American Psychiatric Association, Diagnostic and Sfafisficai Manuai of Mentai
Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association;
2000:375-376.
itary-adrenal axis may contribute
to the clinical presentation of bipo-
lar disorder.̂ "
Non-genetic factors, including
psychological stress, thyroid dis-
ease, and sleep deprivation, may be
closely intertwined with a genetic
predisposition to bipolar disor-
der.""'" One psychodynamic theo-
ry identifies the depressive side of
the disorder as a manifestation of
losses, and the manic side as a
defense against depression,̂ "
Definitions and Diagnostic Criteria
The Diagnostic and Statistical
Manual of Mental Disorders, Fourth
Edition, Text Revision (DSM-IV-TR)
identifies the criteria used to diag-
nose bipolar I disorder, bipolar II
disorder, cyclothymia, and bipolar
disorder, not otherwise specified
(NOS) (Table 1)."̂  To increase
recognition of bipolar disorder, this
diagnosis should be considered in
all patients who present with symp-
toms of a mood disorder.̂  '° Specific
features provide clues to making
an accurate diagnosis. Red nags
include a family history of bipolar
disorder, an early age of onset (<25
years), frequent episodes, rapid
cycling, psychotic features, seasonal
patterns, and poor response to
antidepressants (eg, treatment-
emergent hypomania, lack of
response to multiple trials of differ-
ent antidepressants).'''''"*
In children and adolescents,
NPs need to distinguish bipolar
disorder from other behavioral dis-
orders. Red flags for identifying
bipolar disorder in children and
adolescents include infiated self-
esteem or grandiosity, increased
goal-directed activity, flight of ideas,
decreased need for sleep, excessive
involvement in pleasurable activi-
ties without concern for adverse
consequences, and pronounced
se}aial energy."
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The Mood Disorder Question-
naire (MDQ) is a validated screen-
ing tool for bipolar depression
(Table 2).̂ *̂  This questionnaire can
help identify 70% of patients with
bipolar disorder while eliminat-
ing the diagnosis in 90% of per-
sons without the diagnosis. The
MDQ is easily administered by
primary care providers or it can be
self-administered by patients. It
contains 15 questions focusing on
behavioral symptoms and on the
family and personal history. The
test takes about 5 minutes to com-
plete. Some patients may have
only 3 or 4 positive answers to the
MDQ, which is insufficient to
meet criteria for bipolar disorder
(7 of 13 positive answers). Never-
theless, in these cases, NPs should
be alert for future manifestations
of this illness. The MDQ has
another important function—it
may make patients more aware of
symptoms that they may have dis-




Bipolar disorder is a complicated
diagnosis because of the lack of a
consistent pattern of presentation.
Differentiating bipolar depression
from unipolar depression is a chal-
lenge; misdiagnosis is common. A
chart review of 85 patients with
bipolar or unipolar depression
showed that 56% of the patients
were originally misdiagnosed,"
usually with unipolar depression
or an anxiety disorder.^ '"*'̂ '*
Comorbid psychiatric condi-
tions may obscure the clinical pic-
ture, adding to the difficulty of
making an accurate diagnosis."'^'
Sixty-five percent of bipolar
patients have a comorbid psychi-
atric axis I disorder (ie, a major
mental disorder such as depres-
sion, anxiety, schizophrenia, atten-
tion-deficit hyperactivity disorder,
post-traumatic stress disorder) and
25% have three or more diag-
noses." An NIMH study of patients
with bipolar disorder showed that
42% also met criteria for post-trau-
matic stress disorder.'" Underlying
personality disorders also compli-
cate the picture—many features of
bipolar disorder and borderline
personality disorder overlap.^""
Finally, approximately 60% of
patients with bipolar disorder self-
medicate with alcohol, marijuana,
or other illicit substances, making
accurate diagnosis of bipolar disor-
der even more complicated.^ '^'
Many patients with bipolar
disorder function adequately in
their social life and view their
hypomanic periods as produc-
tive." Thus, they tend to seek med-
ical care only during the depressed
phase of their illness. When
patients are depressed, they may
be unable to recall episodes of
feeling good."' NPs need to bear
in mind that a depressed mood
may not be specific to a depressive
disorder but may also occur transi-
tionally during a manic episode or
pervasively." Therefore, bipolar
disorder needs to be included in
the differential diagnosis whenev-
er a patient presents with symp-
toms of depression.
Distinguishing Bipolar Disorder
from Behavior Disorders in
Children and Adolescents
Identifying bipolar disorder in
young persons is complicated by
the fact that the diagnostic criteria
are based on symptoms found in
adults (research on age-appropri-
ate criteria is limited)."" Mani-
festations of bipolar disorder
typically appear during the teenage
years or early 20s (median age of
onset, 17.5 years).'"•'"̂ '"̂ ••''•"
One challenge in recognizing
bipolar disorder in children and
adolescents is that they may pre-
sent with disruptive behaviors that
can be confused with attention
deficit hyperactivity disorder
(ADHD), oppositional defiant dis-
order (ODD), or conduct disorder
(CD)."""" Also, certain manifes-
tations of bipolar disorder (eg,
excessive talking, distractibility,
increased activity level, restless-
ness, loss of normal social inhibi-
tions) overlap with those of
ADHD. Furthermore, the diag-
noses of ADHD and bipolar disor-
der may coexist.-"
CD, a more severe form of
ODD, manifests in severe behav-
ioral problems such as aggression
toward people and animals,
destruction of property, deceitful-
ness, theft, or serious violation of
rules. Children with bipolar disor-
der may manifest their irritability in
a violent manner as well. Thus, NPs
need to distinguish between the two
disorders. In children with bipolar
disorder, the onset of irritable,
impulsive outbursts is rapid, where-
as in children with ODD or CD, the
onset is slower and progresses ftom
minor infarctions to more severe
rule-breaking. Further, children
with bipolar disorder tend to have
episodic outbursts rather than a
continual progression, and they
generally express guilt and remorse
following an outburst."
When to Refer
In the case of most children and
adolescents, evaluation and man-
agement are considered outside the
scope of primary care practice."
Even psychiatrists and other special-
ists in the field of mental health may
take up to 8 years to accurately diag-
nose bipolar disorder.^' Because
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many patients with bipolar disorder
will first present to a primary care
provider, NPs will still need to pro-
vide a preliminary diagnosis and,
possibly, initiate treatment for high-
ly symptomatic patients before mak-
ing appropriate referral. The
remainder of this article provides
the information that primary care
NPs need to start the process.
Diagnostic and Medical Evaluation
Physical causes, including medical
conditions (Table 3) and use of cer-
tain pharmacologie agents (Table
4), must be excluded when
patients present with symptoms
consistent with a mood disorder.
In addition, patients with bipolar
disorder, as compared with the
general population, have a higher
TABLE 2 MOOD DISORDER QUESTIONNAIRE'
Please answer each questian as best you can. Circle Yes or No.
1. Has there ever been a period of time when you were not your usual self and...
• you felt so good or so hyper that other people thought you were not your normal self or
you were so hyper that you got into trouble?
• you were so irritable that you shouted at people or started fights or arguments?
• you felt much more self-confident than usual?
• you got much less sleep than usual and found you didn't really miss it?
• you were much more talkative or spoke much faster than usual?
• thoughts raced through your head or you couldn't slow your mind down?
• you were so easily distracted by things around you that you had trouble
concentrating or staying on track?
• you had much more energy than usual?
• you were much more active or did many more things than usual?
• you were much more social or outgoing than usual—for example, you telephoned
friends in the middle of the night?
• you were much more interested in sex than usual?
• you did things that were unusual for you or that other people might have thought
were excessive, foolish, or risky?
• spending money got you or your family into trouble?
2. If you circled "Yes" to more than one of the questions above, have several of these




























3. How much of a problem did any of these episodes cause you (eg, being unable to work;
having family, money, or legal troubles; getting into arguments or fights)?
Please circle one response only. No Problem Minor Problem Moderate Problem Serious Problem
4. Have any of your blood relatives (ie, children, siblings, parents, grandparents,
aunts, uncles) had manic-depressive illness or bipolar disorder? Yes No
5. Has a healthcare professional ever told you that you have manic-depressive
illness or bipolar disorder? Yes No
Score:
Question 1 ; 7 out of 13 "Yes" responses; Question 2; 1 positive "Yes" response; Question 3; "Moderate" or "Serious"
Positive Screen: All 3 criteria met in Questions 1, 2, and 3.
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lifetime incidence of many medical
conditions, necessitating careful
history taking and performance of a
physical examination before mak-
ing a diagnosis of bipolar disorder
or beginning a medication regimen.
No single diagnostic study is
used to make the diagnosis of bipo-
lar disorder. However, several labo-
ratory tests must be ordered before
making the diagnosis to rule out an
underlying medical cause that may
mimic or precipitate the depressive
or manic side of bipolar disorder.
Another reason for ordering labora-
tory tests is to ensure that certain
body systems are functioning ade-
quately; otherwise, patients may
not tolerate medications such as
lithium, anticonvulsants, or "atypi-
cal" antipsychotics."
A complete blood cell count
(CBC) with differential will rule
out anemia as a cause of the
depression. These blood tests are
also important because certain
anticonvulsants may depress bone
marrow, and lithium may cause a
reversible increase in the white
blood cell count. A sedimentation
rate is measured to exclude an
underlying disease process such as
systemic lupus erythematosus
(SLE), infection, or malignancy.'*" If
SLE is suspected, then an antinu-
clear antibody test is performed. A
fasting glucose level is ordered to
rule out diabetes mellitus; the
atypical antipsychotics have been
associated with both weight gain
and blood glucose dysregulation.
An electrolyte panel is ordered
because (1) hyponatremia may
manifest as depression, (2) lithium
use may cause renal and/or elec-
trolyte problems, and (3) hypona-
tremia may lead to elevated lithium
levels, possibly resulting in lithium
toxicity. Serum calcium is measured
because hypocalcemia may be asso-
ciated with mental status changes
and because hypercalcemia is asso-
ciated with hyperparathyroidism,
which may cause depression.
Serum protein levels are measured
in patients who present with
depression and loss of appetite/
anorexia; low serum protein levels
may affect the way certain medica-
tions are metabolized. Thyroid
function tests are performed to rule
out hyperthyroidism (associated
with manic symptoms) and
hypothyroidism (associated with
depressive symptoms)."
A toxicology screen is ordered
because persons who abuse alco-
hol or other drugs may present
with symptoms of mania or
depression, and because many
patients with bipolar disorder have
a comorbid drug or alcohol addic-
tion that should be uncovered. An
HIV test is considered in persons at
high risk; AIDS causes changes in
mental status, including depres-
sion. NPs may also consider order-
ing tests to check for syphilis,
which alters mental status. Renal
function tests (serum creatinine,
blood urea nitrogen) are performed
to rule out renal dysfunction,
which may present as depression.
A baseline electrocardiogram
(ECG) is obtained because many
antidepressants (especially the tri-
cyclic antidepressants [TCAs]), the
atypical antipsychotics, and lithi-
um can affect the heart and lead
to rhythm abnormalities.'"
TABLE 3 MEDICAL CONDITIONS THAT MAY CAUSE CHANGES IN MOOD AND BEHAVIOR
NEUROLOGIC DISORDERS: Seizures, tumors, cerebrovascular accident, subdural hematoma/closed head injury,
neurodegenerative diseases, Parkinson's disease, Huntington's disease, Alzheimer's disease, Wilson's disease
ENDOCRINOLOGIC DISORDERS: Thyroid disease, adrenal disease
METABOLIC DISORDERS: Electrolyte imbalance, uremia, thiamine deficiency, vitamin B12 deficiency, porphyrio,
postoperative status
CARDIAC DISORDERS: Coronary artery disease
IMMUNOLOGIC DISORDERS: Systemic lupus erythematosus, fibromyalgia
DEMYELINATING DISEASE: Multiple sclerosis
MALIGNANCY: Pancreatic cancer, calcium-related multiple myeloma
INFECTIOUS DISEASES: Syphilis, encephalitis, HIV infection, hepatitis A or B, infectious mononucleosis, influenza,
Lyme disease, herpes encephalitis
PHARMACOLOGIC-RELATED AND OTHER TOXICITIES: Acute intoxication or withdrawal from prescribed, over-the-
counter, or illicit drugs; heavy metal poisoning; carbon monoxide poisoning
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Pharmacologie Treatment Options
In many cases, treatment for bipo-
lar I disorder is managed by a psy-
chiatrist in an inpatient setting.
Nevertheless, many patients pre-
sent with less overt symptoms in
the primary care setting, and some
patients may resist seeing a mental
healthcare provider. Thus, primary
care NPs need to know the types of
medications that are available to
treat bipolar disorder.
The list includes mood stabilizers
(eg, lithium), anticonvulsants, and
antidepressants, which include selec-
tive serotonin inhibitors (SSRIs),
monoamine oxidase inhibitors
(MAOIs), and TCAs.'' Some
patients with psychotic features
may also require treatment with an
antipsychotic agent, including one
of the newer second-generation
atypical antipsychotics. Table 5 pro-
vides an overview of pharmacolog-
ie treatment strategies.̂ "
Lithium—The first medication
used successfully to treat mania,
lithium (Eskalith® and others)
remains a first-line pharmacologie
option, with data clearly support-
ing its efficacy in reducing suicidal
ideation in patients with bipolar
disorder." Lithium may take sever-
al weeks to achieve a therapeutic
TABLE 4



















































effect; severely impaired patients
may need an additional mood-sta-
bilizing or antipsychotic agent to
treat symptomatology. Side effects
may include nausea, diarrhea,
tremor, polyuria, and polydipsia,
which are managed by reducing
the total daily dose or adjusting the
dosing schedule. Patients on long-
term lithium may develop hypo-
thyroidism and, in rare cases, renal
insufficiency. Serum lithium levels
must be monitored judiciously to
prevent neurotoxicity, which may
occur when peak serum levels
exceed 2.0 mEq per L.*" In general, a
serum lithium level range of 0.5 to
1.4 mEq per L is recommended for
acute treatment and prophylaxis.'"
Because lithium is renally excreted,
NPs must exercise caution when
prescribing it in combination with
nonsteroidal anti-inflammatory
drugs, thiazide diuretics, angio-
tensin-converting enzyme inhibi-
tors or angiotensin II receptor
blockers (these agents may slow
kidney funrtion, causing increased
sertim lithium levels).
Antiepileptic Drugs—AEDs
have become increasingly popular
for patients who need a mood sta-
bilizer. These agents may be used
with lithium or as monotherapy in
patients who have failed lithium
treatment. Valproic acid and its
derivatives (eg, divalproex sodium,
valproate sodium) are considered
first-line agents for patients with
acute manic or mixed episodes, and
are often used for long-term main-
tenance."* The most common side
effects of valproic acid are nausea,
vomiting, diarrhea, and sedation.
NPs should routinely monitor
patients' serum valproate levels,
liver function, and CBC because
serious adverse events, include
hepatotoxicity, pancreatitis, and
thrombocytopenia, may occur.
Valproic acid must be prescribed
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with caution to reproductive-aged
women because this agent is terato-
genic, can induce menstrual irregu-
larities, and can increase the risk of
developing polycystic ovary syn-
drome.'" Carbamazepine extended-
release (Tegretol®-XR, Carbatrol®)
has been approved to treat mania,







ziprasidone (Geodon®), and aripi-
prazole (Abilify®), are commonly
used to treat psychotic symptoms of
bipolar disorder. These agents are
preferable to first-generation agents
(eg, haloperidol, chlorpromazine)
because they are less likely to induce
extrapyramidal symptoms (EPS)
such as akathisia and tardive dyski-
nesia.'" Onset of action is fairly
rapid, and treatment response may
be seen within the first week of use.
Except for clozapine, all of the
atypicals are approved by the Food
and Drug Administration (FDA) as
monotherapy for mania or for use
with mood stabilizers. Olanzapine is
FDA approved for maintenance ther-
apy, and, when used vwth the SSRI
fluoxetine (Prozac®), is approved to
treat bipolar depression. Quetiapine
was recently approved to treat bipo-
lar depression.''
When prescribing atypicals,
NPs need to monitor patients for
EPS, which are managed with anti-
cholinergics, antihistamines, beta
blockers, or benzodiazepines.
Patients using atypicals must also
be monitored for weight gain, dia-
betes, insulin resistance, and alter-
ations in lipid profiles.'"'
Antidepressants and Anxio-
lytics—SSRIs, MAOIs, and TCAs are
often used to treat acute depressive
episodes in patients with bipolar
disorder or to manage pafients who
are lithium refractory." Antidepres-
sants, with the possible exception of
bupropion (Wellbutrin®), can trig-
ger mania in patients with bipolar
disorder, so their use is controver-
sial.*" Benzodiazepines such as lor-
azepam (Ativan®) and donazepam
(Klonopin®) have been used for
rapid treatment of agitation, insom-
nia, and anxiety in patients with
manic or hypomanic symptoms
until the mood stabilizer they are
using reaches a therapeutic effect.
Patients with comorbid psychiatric
problems should be referred to a
psychiatric clinician who has exper-
tise in treating the ñiU spectrum of
psychiatric illnesses.
Cognitive-Behavioral Therapy
Medications alone do not help
patients with bipolar disorder
attain optimal levels of function-
ing." Recent research has suggested
that patients with bipolar disorder
have better outcomes (eg, reduced
likelihood of relapse, improved
adherence to their medication regi-
men) when they receive psychother-
apy such as cognitive-behavioral
therapy (CBT) along with medica-
tion.'"' Patients with bipolar disor-
der need to learn skills to cope
with psychosocial Stressors that
may trigger a symptomatic epi-
sode. CBT can help foster a sense of
personal empowerment while
reducing the social stigma of hav-
ing a mental illness." When treat-
ing bipolar patients, NPs should
refer them to a professional thera-
pist to supplement the plan of care.
Implications for NPs
Misdiagnosing bipolar disorder
can have serious consequences
because morbidity and mortality
(eg, functional impairment, sui-
cide) occur at a higher rate in
patients with bipolar disorder than
in those with major depres-
sion.'"" In all scopes of practice,
bipolar disorder is much less rec-
ognized than unipolar depression.
Approximately 70% of patients
with bipolar disorder have received
at least one misdiagnosis (mean,
3.5 misdiagnoses).'""' Primary
care practitioners are not the only
group of healthcare professionals
with a high rate of misdiagnosis of
bipolar disorder; on average, mental
healthcare providers take up to 8
years to recognize this illness.'' This
delay in diagnosis may be due to the
fart that ofthe two poles of a bipolar
disorder, mania is more dramatic
and has been the major area of
research, to the exclusion of bipolar
depression or mixed states.''""
NPs should follow a systemic
treatment plan in managing bipolar
disorder. This plan may include pre-
scribing medications and making
appropriate referrals to a psychiatric
clinician or to the ED for hospital-
ization in the case of acute mania.
Patients who give any indication
that they are a danger to themselves
or to others, who are gravely dis-
abled or out of control, or who
have a concurrent medical condi-
tion such as liver failure or a cardiac
condition that warrants close moni-
toring should be hospitalized.-"
Finally, NPs need to help de-stig-
matize all forms of mental illness,"''
which can be done by developing
supportive relationships with
patients and their families. Patients
should be empowered with hope,
education, and support. NPs also
must individualize the treatment
plan to the specific characteristics
and patterns of each patient, and
should keep in mind each patient's
underlying co-morbidities and
financial and social situations, which
may all affert treatment success."
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Conclusion
Because of the high prevalence of
bipolar disorder, primary care NPs
will likely encounter patients with
this illness in their practice. Each
patient seen for depression and/or
anxiety should be screened for
bipolar disorder. Early detection of
bipolar illness can help patients
reach a stable mood in a shorter
period of time. Developing a ther-
apeutic alliance with patients can
help ensure adherence to the med-
ication regimen. NPs must use a
collaborative approach, referring
patients to experts in psychiatric
illness, as well as therapists to help
teach patients skills to understand
and cope with their illness. An
individualized treatment plan that
























effective in treating and
preventing mania.
FDA approved. Not as
effective as divalproex in
a randomized blind study,"
May be effective in potients
who have not responded to
Li therapy.'-'
Not FDA approved. No
research studies support







Not FDA approved. No
published controlled trials.
May be useful in rapid-
cycling bipolar disorders
or aggression.













by APA guidelines as




FDA approved since 1978.
Research has indicated Li
to be better than placebo
in prolonging time to




outcomes than with Li








with Li for maintenance
trials, Li superior on
primary measures.
whereas carbamazepine




a prolonged time to
recurrence of a depressive
episode.
CONCERNS
Monitoring blood levels is
critical because of the risk for
toxicity and life-threatening
SE at lithium blood levels
>2.0 mEq/L
Monitoring of blood levels
needed to determine
therapeutic range. Monitor
for hepatic toxicity, increased




response, and SE. Monitor
hématologie parameters and
liver function tests frequently





and acetaminophen. Start at
a low dosage and titrate
slowly to reduce risk of
Stevens-Johnson syndrome.
Do not administer to persons
with any type of rash.
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takes into account the individual's
unique characteristics and under-
lying comorbidities will help
reduce the financial and social
stigmata of this common mental
health problem. •
Jane E. Neu is a board certified psy-
chiatric nurse at Natchaug Hospital
and a family nurse practitioner at
Ledgebrook Family Practice, both in
Mansfield Center, Connecticut.
Susan DeNisco is an associate clini-
cal professor and coordinator of the
Family Nurse Practitioner Program
at Sacred Heart University in
Fairfield, Connecticut. The authors
state that they do not have a finan-
cial interest in or other relationship
with any commercial product named
in this presentation.





















FDA approved alone or
v/ith Li or valproote to
increase antimanic efficacy.
FDA approved for short-term
treatment of acute mania or
mixed episodes associated
with bipolar I.
FDA approved for acute
mania in bipolar I disorder.
May be used in combination
with Li or valproate to
increase antimanic efficacy.
FDA approved os mania
combination therapy.
FDA approved for acute
mania or mixed episodes
associated with bipolar 1.
FDA approved when
combined with fluoxetine.
Not FDA approved as
monotherapy. May be
used in combination with
Li or volproate.




FDA approved in 2001 for
treatment of schizophrenia
and schizoaffective disorder.
Not FDA approved for
bipolar depression.
FDA approved for ocute
mania or mixed episodes






reduce time to recurrence
of mania or depression.
Not FDA approved. May
reduce time to recurrence














may lower oral contraceptive
efficacy. Risk of diabetes. QTc
prolongation. Risk for EPS and
NMS.
Sedation++, weight gain+++.
Risk of diabetes and
dyslipidemia. Risk for EPS and
NMS.
Increased prolactin levels,
weight gain +++. Increased
TG and cholesterol levels. Risk
for EPS and NMS.
Somnolence, dizziness, dry
mouth, constipation. Risk of
weight gain, diabetes, and
dyslipidemia. May increase LFT
values. Risk for EPS and
NMS. Ocular lens changes;
monitor for cataracts q 6 months.
Contraindicated in patients with
history of QT prolongation,
recent Ml, CHE Risk of weight
gain, diabetes, and
dyslipidemia. Risk for EPS and
NMS. Monitor electrolytes.
Lower risk of weight gain than
other atypicals.
Somnolence, headoche,
anxiety, insomnia, Gl upset.
Lower risk for obesity,
diabetes, and dyslipidemia thon
other atypicals. Risk for EPS
ond NMS.
FDA = Food and Drug Administration; APA = American Psychiatric Association; Li = lithium; SE = side effects; GAF = globol assessment of functioning;
EPS = extrapyramidol symptoms; NMS = neuroleptic molignant syndrome; TG = triglycérides; LF = liver function test; Ml = myocardial infarction;
CHF = congestive heart failure; Gl = gastrointestinal.
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